JP2013213055A5 - - Google Patents

Download PDF

Info

Publication number
JP2013213055A5
JP2013213055A5 JP2013147555A JP2013147555A JP2013213055A5 JP 2013213055 A5 JP2013213055 A5 JP 2013213055A5 JP 2013147555 A JP2013147555 A JP 2013147555A JP 2013147555 A JP2013147555 A JP 2013147555A JP 2013213055 A5 JP2013213055 A5 JP 2013213055A5
Authority
JP
Japan
Prior art keywords
composition
urease
tumor
enzyme
targeting moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013147555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013213055A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013213055A publication Critical patent/JP2013213055A/ja
Publication of JP2013213055A5 publication Critical patent/JP2013213055A5/ja
Withdrawn legal-status Critical Current

Links

JP2013147555A 2002-07-18 2013-07-16 癌細胞増殖を阻害するためのウレアーゼの使用 Withdrawn JP2013213055A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39724402P 2002-07-18 2002-07-18
US60/397,244 2002-07-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011161332A Division JP5850561B2 (ja) 2002-07-18 2011-07-22 癌細胞増殖を阻害するためのウレアーゼの使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015199988A Division JP2016014066A (ja) 2002-07-18 2015-10-08 癌細胞増殖を阻害するためのウレアーゼの使用

Publications (2)

Publication Number Publication Date
JP2013213055A JP2013213055A (ja) 2013-10-17
JP2013213055A5 true JP2013213055A5 (enExample) 2014-05-08

Family

ID=30771022

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2004522053A Withdrawn JP2006501196A (ja) 2002-07-18 2003-07-16 癌細胞増殖を阻害するためのウレアーゼの使用
JP2011161332A Expired - Fee Related JP5850561B2 (ja) 2002-07-18 2011-07-22 癌細胞増殖を阻害するためのウレアーゼの使用
JP2013147555A Withdrawn JP2013213055A (ja) 2002-07-18 2013-07-16 癌細胞増殖を阻害するためのウレアーゼの使用
JP2015199988A Withdrawn JP2016014066A (ja) 2002-07-18 2015-10-08 癌細胞増殖を阻害するためのウレアーゼの使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2004522053A Withdrawn JP2006501196A (ja) 2002-07-18 2003-07-16 癌細胞増殖を阻害するためのウレアーゼの使用
JP2011161332A Expired - Fee Related JP5850561B2 (ja) 2002-07-18 2011-07-22 癌細胞増殖を阻害するためのウレアーゼの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015199988A Withdrawn JP2016014066A (ja) 2002-07-18 2015-10-08 癌細胞増殖を阻害するためのウレアーゼの使用

Country Status (22)

Country Link
US (1) US7211250B2 (enExample)
EP (2) EP2324846B1 (enExample)
JP (4) JP2006501196A (enExample)
KR (2) KR101352826B1 (enExample)
CN (1) CN100577203C (enExample)
AU (1) AU2003250658B2 (enExample)
BR (1) BR0312664A (enExample)
CA (1) CA2492472C (enExample)
DK (1) DK1530482T3 (enExample)
ES (1) ES2443416T3 (enExample)
IL (1) IL166249A (enExample)
MX (1) MXPA05000778A (enExample)
NO (1) NO336811B1 (enExample)
NZ (1) NZ538284A (enExample)
PL (1) PL217626B1 (enExample)
PT (1) PT1530482E (enExample)
RU (1) RU2326691C2 (enExample)
SI (1) SI1530482T1 (enExample)
TR (1) TR200500108T2 (enExample)
UA (1) UA81634C2 (enExample)
WO (1) WO2004009112A1 (enExample)
ZA (1) ZA200500423B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264800B2 (en) * 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
US7672704B2 (en) * 2002-09-11 2010-03-02 Duke University Methods and compositions for blood pool identification, drug distribution quantification and drug release verification
US7769423B2 (en) * 2002-09-11 2010-08-03 Duke University MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting
CA2543200A1 (en) * 2003-10-24 2005-05-06 National Research Council Of Canada Ligand-pseudoreceptor system for generation of adenoviral vectors with altered tropism
IL182956A0 (en) * 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
AU2014252666B2 (en) * 2013-04-08 2017-02-02 Helix Biopharma Corp. Use of antibody-urease conjugates for diagnostic and therapeutic purposes
NZ733669A (en) * 2015-01-23 2019-03-29 Helix Biopharma Corp Antibody-urease conjugates for therapeutic purposes
US10640806B2 (en) 2016-09-24 2020-05-05 Helix Biopharma Corp. Restoring function of tumour acidified T cells
US20180243437A1 (en) * 2017-01-05 2018-08-30 Heman Lap Man CHAO Anti-vegfr-2 urease conjugates
CN115666571B (zh) * 2020-05-20 2024-11-05 美德阿利克斯株式会社 含有阿扑吗啡的经皮吸收型制剂
CA3182871A1 (en) * 2020-06-15 2021-12-23 Kortuc Inc. Sensitizer for cancer treatment
CN113433087A (zh) * 2021-06-22 2021-09-24 中南大学 一种尿素浓度快速检测方法及检测传感器和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2965725D1 (en) 1978-07-19 1983-07-28 Patrick Couvreur Biodegradable nanoparticles, pharmaceutical compositions containing them and process for their preparation
US4489055A (en) 1978-07-19 1984-12-18 N.V. Sopar S.A. Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
FR2504408B1 (fr) 1981-04-24 1986-02-14 Couvreur Patrick Procede de preparation de particules submicroscopiques, particules ainsi obtenues et compositions pharmaceutiques les contenant
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0092227B1 (en) 1982-04-19 1988-07-27 Nissan Motor Co., Ltd. Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4824783A (en) 1983-12-20 1989-04-25 Enichem S.P.A. Oxidized sulfur derivatives of diaminophosphinyl compounds as urease inhibitors
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
EP0188256B1 (en) 1985-01-14 1991-08-21 NeoRx Metal radionuclide labeled proteins for diagnosis and therapy
US4837380A (en) * 1985-09-30 1989-06-06 Regents Of University Of California Liposome-calcitonin preparation
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4680333A (en) 1986-04-14 1987-07-14 National Starch And Chemical Corporation Removable hot melt pressure sensitive adhesive
US4867962A (en) 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
FR2637612B1 (fr) 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
EP0460607A3 (en) * 1990-06-05 1992-04-01 Bristol-Myers Squibb Company Novel monoclonal antibody to novel antigen associated with human tumors
US5298399A (en) 1990-08-10 1994-03-29 Sapporo Breweries Limited Gene and process for producing a thermostable urease
US5140100A (en) 1990-12-28 1992-08-18 Cedars-Sinai Medical Center Protein that inhibits production of human choriogonadotropin
FR2683159B1 (fr) 1991-10-31 1994-02-25 Coletica Procede de fabrication de nanocapsules a paroi a base de proteines reticulees; nanocapsules ainsi obtenues et compositions cosmetiques, pharmaceutiques et alimentaires en comportant application.
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
WO1993020221A1 (en) * 1992-04-03 1993-10-14 Young Alexander T Gene therapy using targeted viral vectors
US6358490B2 (en) 1992-06-09 2002-03-19 Neorx Corporation Three-step pretargeting methods and compounds
US5976535A (en) 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
GB9300875D0 (en) 1993-01-18 1993-03-10 Ucb Sa Nanocapsule containing pharmaceutical compositions
WO1994018955A1 (en) 1993-02-22 1994-09-01 Alza Corporation Compositions for oral delivery of active agents
WO1995014093A1 (en) 1993-05-19 1995-05-26 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions and nucleic acid sequences encoding said polypeptides
JP3872813B2 (ja) 1994-05-18 2007-01-24 エス．ピー．アイ． シンセティック ペプチデス インコーポレイテッド ヘテロダイマーポリペプチド免疫原キャリア組成物および方法
GB9417873D0 (en) 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
US5886143A (en) 1994-12-07 1999-03-23 Neorx Corporation Hepatic-directed compounds and reagents for preparation thereof
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
FR2732605B1 (fr) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
ATE214101T1 (de) * 1995-09-06 2002-03-15 Austrian Nordic Biotherapeutic Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv
AU1846297A (en) 1996-01-31 1997-08-22 Regents Of The University Of California, The Method for inhibiting tumor cell growth
US6395712B1 (en) 1996-03-20 2002-05-28 Board Of Regents, The University Of Texas System Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy
JPH1017492A (ja) * 1996-07-02 1998-01-20 Fuji Yakuhin Kogyo Kk 腫瘍細胞増殖抑制剤
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US5750496A (en) * 1996-08-12 1998-05-12 Utah State University Method of controlling cryptosporidium infectons using protease inhibitors
EP0824019B1 (en) * 1996-08-13 2002-11-20 Quest International B.V. Inhibition or reduction of oral malodour
JP2001503396A (ja) 1996-10-11 2001-03-13 アルザ コーポレイション 治療用リポソーム組成物および方法
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
CN1181422A (zh) * 1996-10-31 1998-05-13 上海市肿瘤研究所 与生长因子受体结合的多肽所构建的基因转移载体
US6180114B1 (en) 1996-11-21 2001-01-30 University Of Washington Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
US6045774A (en) 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
GB9703633D0 (en) 1997-02-21 1997-04-09 Imp Cancer Res Tech Cancer therapy
US6190923B1 (en) 1997-09-05 2001-02-20 David K. Johnson Diethylenetriamine-N,N′,N″-triacetic acid derivatives
FR2772025B1 (fr) 1997-12-10 2000-03-03 Guerbet Sa Chelates metalliques de macrocycles polyaminocarboxyliques et leur application a l'imagerie par resonance magnetique
US6426086B1 (en) * 1998-02-03 2002-07-30 The Regents Of The University Of California pH-sensitive, serum-stable liposomes
PT1122262E (pt) * 1998-10-16 2010-01-27 Otsuka Pharma Co Ltd Péptidos específicos de zonas neovasculares
FR2790405B1 (fr) 1999-03-02 2001-04-20 Oreal Nanocapsules a base de polymeres dendritiques
AU5646800A (en) 1999-03-02 2000-09-21 Helix Biopharma Corporation Card-based biosensor device
US6159443A (en) 1999-04-29 2000-12-12 Vanderbilt University X-ray guided drug delivery
RU2270029C2 (ru) * 1999-06-25 2006-02-20 Джинентех, Инк. ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ ОБЛАДАЕТ СПОСОБНОСТЬЮ СВЯЗЫВАТЬ ErbB2 И БЛОКИРОВАТЬ АКТИВАЦИЮ ЛИГАНДОМ РЕЦЕПТОРА ErbB (ВАРИАНТЫ) И КОМПОЗИЦИЯ ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ РАКА, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО
US6307372B1 (en) 1999-11-02 2001-10-23 Glaxo Wellcome, Inc. Methods for high throughput chemical screening using magnetic resonance imaging
WO2001037721A2 (en) 1999-11-22 2001-05-31 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
US20020041898A1 (en) 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
AU2001280105A1 (en) * 2000-08-22 2002-03-04 Kyowa Hakko Kogyo Co. Ltd. Methof of regulating apoptosis and apoptosis-regulatory polypeptide
WO2003032814A2 (en) * 2001-10-16 2003-04-24 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2013213055A5 (enExample)
Yin et al. Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy
Gerber et al. Combining antibody–drug conjugates and immune-mediated cancer therapy: what to expect?
CN111194232A (zh) 用于x射线诱导的光动力学疗法、放射疗法、放射动力学疗法、化学疗法、免疫疗法以及它们的任何组合的纳米级金属有机层和金属有机纳米片
JP2019501204A5 (enExample)
CL2011003052A1 (es) Compuesto 8-(2,4-dimetoxi-pirimidin-5-il)-1-(1-etil-3-metil-1h-pirazol-4-il)-3-metil-1,3-dihidro-imidazo[4,5-c]quinolin-2-ona; su composicion farmaceutica; util en el tratamiento de enfermedades dependientes de la cinasa de lipido y/o de proteina, en el tratamiento de enfermedades proliferativas, tales como tumores y carcinomas de cerebro, riñon, higado, entre otras.
JP2022505041A (ja) Ｄｎａアルキル化剤及びａｔｒ阻害剤を使用する併用療法
JP2019501873A5 (enExample)
KR20250053841A (ko) 암의 치료 및/또는 예방을 위한 의약품
BRPI0608175A2 (pt) método de eliminação de população de células heterogêneas ou mistas em tumores, assim como compostos maitansinóides
CN111565742B (zh) 使用axl诱骗受体治疗转移性癌症的方法
Choi et al. A phase I study of nimotuzumab in combination with radiotherapy in stages IIB–IV non-small cell lung cancer unsuitable for radical therapy: Korean results
JP2020505433A5 (enExample)
RU2016110874A (ru) Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний
RU2018105923A (ru) Способы лечения рака с использованием апилимода
JP2018525358A5 (enExample)
RU2326691C2 (ru) Использование уреазы для ингибирования роста раковых клеток
US20220211883A1 (en) Fap-activated radiotheranostics and uses related thereto
Kim et al. Combination therapy of cilengitide with belotecan against experimental glioblastoma
Mani et al. ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo
Mellinghoff et al. PL3. 1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1
US11419894B2 (en) Modified natural killer cells for the treatment of cancer
WO2016191703A3 (en) Tumor deliverable iron and protein synthesis inhibitors as a new class of drugs for the diagnosis and treatment of cancer
Dômont et al. Adjuvant chemotherapy in early-stage non-small cell lung cancer
Choi et al. Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer